ACOSOG Z0010: A multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer

R Cote; A. E Giuliano; D Hawes; K. V Ballman; P. W Whitworth; P. W Blumencranz; D. S Reintgen; M Morrow; A. M Leitch; K Hunt

doi:10.1200/jco.2010.28.18_suppl.cra504

Back

ACOSOG Z0010: A multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer

Journal article

Peer reviewed

ACOSOG Z0010: A multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer

R Cote, A. E Giuliano, D Hawes, K. V Ballman, P. W Whitworth, P. W Blumencranz, D. S Reintgen, M Morrow, A. M Leitch and K Hunt

Journal of clinical oncology, Vol.28(18_suppl), pp.CRA504-CRA504

2010-06-20

DOI: https://doi.org/10.1200/jco.2010.28.18_suppl.cra504

Abstract

CRA504 Background: SN biopsy (SNB) with immunohistochemistry (IHC) of histologically negative SN identifies metastases (mets) not seen by standard histology. The impact of IHC-detected BM mets has been reported in several large single-institution studies. 5,539 patients (pts) were entered into this prospective multicenter observational study to determine the clinical significance of SN and BM mets. Methods: Patients underwent lumpectomy and SNB with bilateral iliac crest BM aspiration. BM and histologically negative SN were evaluated with IHC in a central laboratory (results not clinically reported). Overall survival (OS), disease-free survival, and locoregional recurrence were determined. Results with OS (the primary endpoint) are reported here. Results: SN were successfully identified in 5,184 of 5,485 pts (94.5%). Histologic SN mets were found in 1,239 pts (23.9%). IHC detected an additional 350 pts (10.5%) with SN mets. BM mets were identified by IHC in 105 of 3491 examined (3.0%). 5-yr overall survival is shown in the Table . BM IHC positivity significantly predicted decreased OS (p=0.015). A multivariable analysis that included SN and BM status, ER, PR, grade, size, and age showed that neither IHC detected mets in SN (p=0.66) or BM (p=0.08) were independent predictors of OS, although BM status showed a strong trend. Conclusions: The detection of BM mets by IHC in pts with clinical T1/2 N0M0 breast cancer identifies those pts at significantly increased risk for death; the impact of BM mets on outcome supports and confirms prior studies. In this study, SN IHC-detected mets appear to have no significant impact on OS. The routine examination of SN by IHC is not supported in this patient population by this study. [Table: see text] [Table: see text]

Metrics

58 Record Views

33 Times Cited - Web of Science

See more details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.119 Breast Cancer Scanning; 1.119.574 Lymphedema
Web Of Science research areas: Oncology
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: ACOSOG Z0010: A multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer
Creators: R Cote - University of Miami Leonard M. Miller School of Medicine, Miami, FL; John Wayne Cancer Institute, Santa Monica, CA; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Mayo Clinic, Rochester, MN; Nashville Breast Center, Nashville, TN; Morton Plant Hospital, Clearwater, FL; Lakeland Regional Cancer Center, Lakeland, FL; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas Southwestern Medical Center, Dallas, TX; M. D. Anderson Cancer Center, Houston
A. E Giuliano - University of Miami Leonard M. Miller School of Medicine, Miami, FL; John Wayne Cancer Institute, Santa Monica, CA; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Mayo Clinic, Rochester, MN; Nashville Breast Center, Nashville, TN; Morton Plant Hospital, Clearwater, FL; Lakeland Regional Cancer Center, Lakeland, FL; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas Southwestern Medical Center, Dallas, TX; M. D. Anderson Cancer Center, Houston
D Hawes - University of Miami Leonard M. Miller School of Medicine, Miami, FL; John Wayne Cancer Institute, Santa Monica, CA; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Mayo Clinic, Rochester, MN; Nashville Breast Center, Nashville, TN; Morton Plant Hospital, Clearwater, FL; Lakeland Regional Cancer Center, Lakeland, FL; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas Southwestern Medical Center, Dallas, TX; M. D. Anderson Cancer Center, Houston
K. V Ballman - University of Miami Leonard M. Miller School of Medicine, Miami, FL; John Wayne Cancer Institute, Santa Monica, CA; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Mayo Clinic, Rochester, MN; Nashville Breast Center, Nashville, TN; Morton Plant Hospital, Clearwater, FL; Lakeland Regional Cancer Center, Lakeland, FL; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas Southwestern Medical Center, Dallas, TX; M. D. Anderson Cancer Center, Houston
P. W Whitworth - University of Miami Leonard M. Miller School of Medicine, Miami, FL; John Wayne Cancer Institute, Santa Monica, CA; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Mayo Clinic, Rochester, MN; Nashville Breast Center, Nashville, TN; Morton Plant Hospital, Clearwater, FL; Lakeland Regional Cancer Center, Lakeland, FL; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas Southwestern Medical Center, Dallas, TX; M. D. Anderson Cancer Center, Houston
P. W Blumencranz - University of Miami Leonard M. Miller School of Medicine, Miami, FL; John Wayne Cancer Institute, Santa Monica, CA; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Mayo Clinic, Rochester, MN; Nashville Breast Center, Nashville, TN; Morton Plant Hospital, Clearwater, FL; Lakeland Regional Cancer Center, Lakeland, FL; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas Southwestern Medical Center, Dallas, TX; M. D. Anderson Cancer Center, Houston
D. S Reintgen - University of Miami Leonard M. Miller School of Medicine, Miami, FL; John Wayne Cancer Institute, Santa Monica, CA; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Mayo Clinic, Rochester, MN; Nashville Breast Center, Nashville, TN; Morton Plant Hospital, Clearwater, FL; Lakeland Regional Cancer Center, Lakeland, FL; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas Southwestern Medical Center, Dallas, TX; M. D. Anderson Cancer Center, Houston
M Morrow - University of Miami Leonard M. Miller School of Medicine, Miami, FL; John Wayne Cancer Institute, Santa Monica, CA; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Mayo Clinic, Rochester, MN; Nashville Breast Center, Nashville, TN; Morton Plant Hospital, Clearwater, FL; Lakeland Regional Cancer Center, Lakeland, FL; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas Southwestern Medical Center, Dallas, TX; M. D. Anderson Cancer Center, Houston
A. M Leitch - University of Miami Leonard M. Miller School of Medicine, Miami, FL; John Wayne Cancer Institute, Santa Monica, CA; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Mayo Clinic, Rochester, MN; Nashville Breast Center, Nashville, TN; Morton Plant Hospital, Clearwater, FL; Lakeland Regional Cancer Center, Lakeland, FL; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas Southwestern Medical Center, Dallas, TX; M. D. Anderson Cancer Center, Houston
K Hunt - University of Miami Leonard M. Miller School of Medicine, Miami, FL; John Wayne Cancer Institute, Santa Monica, CA; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Mayo Clinic, Rochester, MN; Nashville Breast Center, Nashville, TN; Morton Plant Hospital, Clearwater, FL; Lakeland Regional Cancer Center, Lakeland, FL; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas Southwestern Medical Center, Dallas, TX; M. D. Anderson Cancer Center, Houston
Publication Details: Journal of clinical oncology, Vol.28(18_suppl), pp.CRA504-CRA504
Academic Unit: Miller School of Medicine; UMMG Department of Pathology
Language: English
Resource Type: Journal article
Record Identifier: 991031599652902976